PHASE 1A CLINICAL TRIAL WITH KB2115 SUCCESSFULLY COMPLETED

Karo Bio has completed the first single ascending dose part of its phase 1 study for KB2115 with a successful outcome. The study, conducted with overweight but healthy individuals with elevated blood lipids, shows that KB2115 was well tolerated and no adverse events was observed.

In preclinical studies KB2115 selectively stimulates the thyroid hormone receptor and thereby increases the body’s energy consumption and reduces body weight. The compound also markedly reduces blood lipids and blood glucose and has a broad therapeutic range. The phase I study is a randomized, double-blind and placebo-controlled study in healthy but overweight males and females with dyslipidemia. The primary objective is to determine the short term safety and tolerability of single dose (phase Ia) and multiple oral doses of KB2115 administered daily over a 14 day period (phase Ib). In addition to safety and tolerability, effects of KB2115 on blood lipids and metabolic markers have been measured. The phase Ia single dose part of the study has now been completed with a successful outcome. No adverse findings have been documented and positive effects on blood lipids have been recorded. Karo Bio has now initiated the multi dose phase Ib part of the study. KARO BIO AB For further information, please contact: Per Olof Wallström, President & Chief Executive Officer Cell phone: +46 70 942 9520 Per Otteskog, Senior Vice President Corporate Development Telephone: +46 8 608 60 18 Cell phone: +46 70 6327527 Facts about Karo Bio Karo Bio is an innovative drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. Karo Bio is listed on the Stockholm stock exchange (Reuters: KARO.ST) since 1998. The Company has expanded from being a drug discovery company by adding in-housel development resources and competence for development of drugs to treat metabolic diseases. The Company has a strong project portfolio primarily targeting diseases such as diabetes, obesity, atherosclerosis and dyslipidemia. In addition, Karo Bio has two strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases. This press release is also available online at: www.karobio.com and www.waymaker.net.